Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Which salad do you believe is a definitive group pleaser? Vote! - 2How a cocktail of rogue storms and climate chaos unleashed deadly flooding across Asia
- 3FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- 4I asked ChatGPT who would win a Golden Globes. Here's what it got right — and totally wrong.
- 5One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
- The Solution to Individual budget: Dominating Cash The board
- Nature's Best: A Manual for Beautiful Train Rides
- Pick Your Favored kind of sandwich
- Tzrifin base exhibition reveals Hamas and Hezbollah arms, showing structure behind attacks
- Thermo Fisher wins contracts as pharma shifts production to US, CEO says
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
- Extraordinary Guinness World Records That Will Astound You
- The gay hockey show no one saw coming — and everyone is suddenly obsessed with
- Hamas hands over another body in the Gaza Strip
